Literature DB >> 23176078

Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women.

Shelly L Gray1, Aaron K Aragaki, Michael J LaMonte, Barbara B Cochrane, Charles Kooperberg, Jennifer G Robinson, Nancy F Woods, Andrea Z LaCroix.   

Abstract

OBJECTIVES: To examine associations between angiotensin-converting enzyme (ACE) inhibitor and statin medications and baseline and mean annual change in physical performance measures and muscle strength in older women.
DESIGN: Prospective cohort study. PARTICIPANTS: Participants from the Women's Health Initiative Clinical Trials aged 65 to 79 at baseline who had physical performance measures, self-report of health insurance, and no prior history of stroke or congestive heart failure were included (N = 5,777). Women were recruited between 1993 and 1998. MEASUREMENTS: Medication use was ascertained through a baseline inventory. Physical performance measures (timed 6-m walk, repeated chair stands in 15 seconds) and grip strength were assessed at baseline and follow-up Years 1, 3, and 6. Multivariable-adjusted linear repeated-measures models were adjusted for demographic and health characteristics.
RESULTS: ACE inhibitor use was associated with lower mean grip strength at baseline (22.40 kg, 95% confidence interval (CI) = 21.89-22.91 vs 23.18 kg, 95% CI 23.02-23.34; P = .005) and greater mean annual change in number of chair stands (-0.182, 95% CI -0.217 to -0.147 vs -0.145, 95% CI -0.156 to -0.133; P = .05) than nonuse. Statin use was not significantly associated with baseline measures or mean annual change for any outcome. A subgroup analysis suggested that statin use was associated with less mean annual change in chair stands (P = .006) in the oldest women.
CONCLUSION: These results do not support an association between statin or ACE inhibitor use and slower decline in physical performance or muscle strength and thus do not support the use of these medications for preserving functional status in older adults.
© 2012, Copyright the Authors Journal compilation © 2012, The American Geriatrics Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23176078      PMCID: PMC3521070          DOI: 10.1111/jgs.12029

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  44 in total

1.  Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery.

Authors:  J M Guralnik; L Ferrucci; C F Pieper; S G Leveille; K S Markides; G V Ostir; S Studenski; L F Berkman; R B Wallace
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-04       Impact factor: 6.053

2.  Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension.

Authors:  Gina D Schellenbaum; Nicholas L Smith; Susan R Heckbert; Thomas Lumley; Thomas D Rea; Curt D Furberg; Mary F Lyles; Bruce M Psaty
Journal:  J Am Geriatr Soc       Date:  2005-11       Impact factor: 5.562

3.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

4.  Meaningful change and responsiveness in common physical performance measures in older adults.

Authors:  Subashan Perera; Samir H Mody; Richard C Woodman; Stephanie A Studenski
Journal:  J Am Geriatr Soc       Date:  2006-05       Impact factor: 5.562

5.  Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Authors:  Eric Bruckert; Gilles Hayem; Sylvie Dejager; Caroline Yau; Bernard Bégaud
Journal:  Cardiovasc Drugs Ther       Date:  2005-12       Impact factor: 3.727

6.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.

Authors:  P M Ridker; N Rifai; M A Pfeffer; F Sacks; E Braunwald
Journal:  Circulation       Date:  1999-07-20       Impact factor: 29.690

7.  Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.

Authors:  Anna A Ahimastos; Adam Lawler; Christopher M Reid; Peter A Blombery; Bronwyn A Kingwell
Journal:  Ann Intern Med       Date:  2006-05-02       Impact factor: 25.391

8.  Statin-related adverse events: a meta-analysis.

Authors:  Matthew A Silva; Anna C Swanson; Pritesh J Gandhi; Gary R Tataronis
Journal:  Clin Ther       Date:  2006-01       Impact factor: 3.393

9.  Statin use and functional decline in patients with and without peripheral arterial disease.

Authors:  Jay Giri; Mary M McDermott; Philip Greenland; Jack M Guralnik; Michael H Criqui; Kiang Liu; Luigi Ferrucci; David Green; Joseph R Schneider; Lu Tian
Journal:  J Am Coll Cardiol       Date:  2006-02-09       Impact factor: 24.094

10.  Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability.

Authors:  J M Guralnik; L Ferrucci; E M Simonsick; M E Salive; R B Wallace
Journal:  N Engl J Med       Date:  1995-03-02       Impact factor: 91.245

View more
  21 in total

1.  Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

Review 2.  Rewinding sarcopenia: a narrative review on the renin-angiotensin system.

Authors:  Timur Ekiz; Murat Kara; Ayşe Merve Ata; Vincenzo Ricci; Özgür Kara; Fırat Özcan; Levent Özçakar
Journal:  Aging Clin Exp Res       Date:  2021-01-04       Impact factor: 3.636

3.  Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11-16       Impact factor: 2.205

4.  Association between Statin Use and Physical Function among Older Chinese Inpatients with Type 2 Diabetes.

Authors:  Y Li; X Yang; Y Zou; J Li; Q Sun; X Jing; M Yang; S Wang; B Dong
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

5.  Effect of Statin Use on Mobility Disability and its Prevention in At-risk Older Adults: The LIFE Study.

Authors:  Rebecca M Henderson; Laura Lovato; Michael E Miller; Roger A Fielding; Tim S Church; Anne B Newman; Thomas W Buford; Marco Pahor; Mary M McDermott; Randall S Stafford; David S H Lee; Stephen B Kritchevsky
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-03-17       Impact factor: 6.053

6.  Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II).

Authors:  Dominik Spira; Jeremy Walston; Nikolaus Buchmann; Jivko Nikolov; Ilja Demuth; Elisabeth Steinhagen-Thiessen; Rahel Eckardt; Kristina Norman
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

7.  Lipid-lowering drugs associated with slower motor decline in the elderly adults.

Authors:  Julien Dumurgier; Archana Singh-Manoux; Béatrice Tavernier; Christophe Tzourio; Alexis Elbaz
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-10-04       Impact factor: 6.053

Review 8.  Effect of Angiotensin-Converting Enzyme Inhibitors on Physical Function in Elderly Subjects: A Systematic Review and Meta-Analysis.

Authors:  Ling-shan Zhou; Ling-jie Xu; Xue-qing Wang; Yi-huan Huang; Qian Xiao
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

9.  Associations Between Statin Use and Physical Function in Older Adults from The Netherlands and Australia: Longitudinal Aging Study Amsterdam and Australian Longitudinal Study on Women's Health.

Authors:  Laurette van Boheemen; Susan E Tett; Evelien Sohl; Jacqueline G Hugtenburg; Natasja M van Schoor; G M E E Peeters
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

10.  Gait Performance in Hypertensive Patients on Angiotensin-Converting Enzyme Inhibitors.

Authors:  Claudene J George; Joe Verghese
Journal:  J Am Med Dir Assoc       Date:  2016-05-18       Impact factor: 4.669

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.